No secondary impact of ivermectin mass drug administration for onchocerciasis elimination on the prevalence of scabies in northwestern Ethiopia
Transactions of The Royal Society of Tropical Medicine and Hygiene · 2024
DOI: 10.1093/trstmh/trad061 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transactions of The Royal Society of Tropical Medicine and Hygiene, 2024. Verfasst von Robel Yirgu und 6 weiteren Autor:innen. Beteiligte Einrichtung: NIHR Global Health Research Unit on Neglected Tropical Diseases, Brighton and Sussex Medical School, Falmer, Brighton BN1 9PX, UK. Hauptthemen laut MEDLINE: Scabies, Onchocerciasis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: National Institute for Health and Care Research, Department of Health and Social Care.
Abstract (Originalsprache)
Background
Mass drug administration (MDA) is among the five major strategies that are currently in use to control, eliminate or eradicate Neglected Tropical Diseases (NTDs). Optimising MDA to control multiple NTDs maximises impact. The objective of this study is to estimate the secondary impact of ivermectin MDA for onchocerciasis on the prevalence of scabies.
Methods
This quasi-experimental study was conducted in Ayu Guagusa district, northwestern Ethiopia. Scabies prevalence was estimated in surveys before the MDA, at 6 and 12 months afterwards. The sample size was 1437 people from a panel of 381 randomly selected study households. Multistage sampling was employed in randomly selecting six kebeles (the lowest administrative unit) with respective gotes (small villages) and households. All members of the selected households were invited to participate in the study and participants who were available in all three surveys formed a cohort.
Results
Scabies prevalence was similar prior to the MDA (13.4%, 95% CI 11.7 to 15.2%) and 6 months after (11.7%, 95% CI 10.1 to 13.2%) but was substantially greater at 12 months (22.1%, 95% CI 20.1 to 24.1%). The 6-month incidence and disappearance rates were 10.8% (95% CI 8.8 to 13.2%) and 82.6% (95% CI 75.0 to 88.6%), respectively.
Conclusions
Ivermectin MDA for onchocerciasis was not observed to have a secondary impact on the prevalence of scabies over the follow-up period of 12 months.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- NIHR Global Health Research Unit on Neglected Tropical Diseases, Brighton and Sussex Medical School, Falmer, Brighton BN1 9PX, UK.
- School of Public Health, Addis Ababa University, Addis Ababa, 9086, Ethiopia.
- Center for Innovative Drug Development and Therapeutic Trials for Africa (CDT)-Africa, Addis Ababa University, Addis Ababa, 9086, Ethiopia.
- Department of Primary Care and Public Health, Brighton and Sussex Medical School, Falmer, UK.
ORCID-Profile: Gail Davey
Förderung
- National Institute for Health and Care Research
- Department of Health and Social Care
Zitieren
APA
Yirgu, R., Middleton, J., Fekadu, A., Davey, G., Bremner, S., Jones, C. I., & Cassell, J. A. (2024). No secondary impact of ivermectin mass drug administration for onchocerciasis elimination on the prevalence of scabies in northwestern Ethiopia. Transactions of The Royal Society of Tropical Medicine and Hygiene. https://doi.org/10.1093/trstmh/trad061
Vancouver
Yirgu R, Middleton J, Fekadu A, Davey G, Bremner S, Jones CI, et al. No secondary impact of ivermectin mass drug administration for onchocerciasis elimination on the prevalence of scabies in northwestern Ethiopia. Transactions of The Royal Society of Tropical Medicine and Hygiene. 2024. doi:10.1093/trstmh/trad061
BibTeX
@article{Yirgu2024,
author = {Yirgu, Robel and Middleton, Jo and Fekadu, Abebaw and Davey, Gail and Bremner, Stephen and Jones, Christopher Iain and Cassell, Jackie A},
title = {No secondary impact of ivermectin mass drug administration for onchocerciasis elimination on the prevalence of scabies in northwestern Ethiopia},
journal = {Transactions of The Royal Society of Tropical Medicine and Hygiene},
year = {2024},
doi = {10.1093/trstmh/trad061}
}
EUVIMED